TaiMed Biologics Inc. (4147.TWO)

TWD 82.5

(-0.48%)

Market Cap (In TWD)

22.52 Billion

Revenue (In TWD)

491.77 Million

Net Income (In TWD)

-194.81 Million

Avg. Volume

650.72 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
66.6-116.5
PE
-
EPS
-
Beta Value
0.334
ISIN
TW0004147004
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Chin-Ming Chang Ph.D.
Employee Count
-
Website
https://www.taimedbiologics.com
Ipo Date
2012-06-20
Details
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.